Amarin Corporation highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the… read more.
NICE(UK): NICE is unable to make a recommendation about the use in the NHS of nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years…. read more.
Incyte announced new data from the Phase IIIb TRuE-AD4 study evaluating the efficacy and safety of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had… read more.
Shionogi & Co., Ltd. announced the launch of a new formulation of the anti-influenza virus drug Xofluza (baloxavir marboxil) – Xofluza Granules 2%. Until now, Xofluza has only… read more.
Novo Nordisk presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver Meeting 2025, in Washington, D.C., evaluating the effects… read more.
Lundbeck announced the acceptance of its new drug application (NDA) for Vyepti (eptinezumab) by the Ministry of Health, Labor and Welfare (MHLW) in Japan. The submission reflects the… read more.
Roche announced that it has received CE mark for its Elecsys Dengue Ag test – a high-throughput, fully automated immunoassay to be used as an aid in the… read more.
Medtronic plc announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to evaluate the safety and effectiveness of its Hugo robotic-assisted surgery (RAS) system… read more.
NICE (UK): Delgocitinib can be used, within its marketing authorisation, as an option to treat moderate to severe chronic hand eczema in adults when topical corticosteroids have not… read more.
NICE (UK): Sparsentan can be used as option to treat primary immunoglobulin A nephropathy (IgAN) in adults with a: i) urine protein-to-creatinine ratio (UPCR) of 85 mg/mmol or… read more.
Pelthos Therapeutics Inc. announced it has acquired the U.S. marketing rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera Inc. and Ferrer Internacional S.A. (the Xepi is a non-fluorinated… read more.
Roche announced that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition,… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
